Conference call and webcast to be held at
8:30 a.m. ET
NEW
HAVEN, Conn., March 9,
2025 /PRNewswire/ -- Trevi Therapeutics,
Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in patients with
idiopathic pulmonary fibrosis (IPF) and refractory chronic cough
(RCC), today announced a conference call and live webcast taking
place tomorrow, Monday, March 10th,
2025, at 8:30 a.m. ET, to
share topline results from the Phase 2a RIVER trial of Haduvio in
patients with refractory chronic cough.
Conference Call
The Company will host a conference
call and webcast to review the topline results. The live webcast,
including audio and presentation slides, will be accessible at the
time of the meeting and can be accessed here. To participate in the
conference call by phone, please dial (877) 870 4263 (domestic) or
(412) 317 0790 (international) and ask to join the Trevi
Therapeutics call. No code is necessary for access. An archived
replay of the webcast will also be available for 30 days on the
Company's website following the event.
About Refractory Chronic Cough (RCC)
Refractory chronic cough has no approved therapies in the U.S. and
is defined as a persistent cough lasting >8 weeks despite
treatment for an underlying condition (i.e., asthma,
gastroesophageal reflux disease, non-asthmatic eosinophilic
bronchitis, and upper airway cough syndrome or post-nasal drip) and
includes unexplained chronic cough. RCC affects ~2-3 million
patients in the U.S. and is caused by cough reflex hypersensitivity
in both the central and peripheral nerves. It is a highly
debilitating disease and accompanied by a wide range of
complications, ranging from urinary incontinence in females to
sleep disruption and social embarrassment that causes significant
social and economic burdens for patients and those around
them.
About Trevi Therapeutics, Inc.
Trevi Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine extended-release)
for the treatment of chronic cough in patients with idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Haduvio acts on the cough reflex arc both centrally and
peripherally as a kappa agonist and a mu antagonist (KAMA), which
are opioid receptors that play a key role in controlling cough
hypersensitivity. Nalbuphine is not currently scheduled by the U.S.
Drug Enforcement Agency.
Chronic cough is highly prevalent in IPF patients, impacting up
to 85% of the IPF population. There are ~140,000 U.S. IPF patients
and the impact of chronic cough is significant with patients
coughing up to 1,500 times per day. This consistent cough, and any
associated damage, may lead to worsening disease, a higher risk of
progression, death, or need for lung transplant. Chronic cough also
often leads to a decline in patients' social, physical, and
psychological quality of life. There are no approved therapies for
the treatment of chronic cough in patients with IPF and current
off-label treatment options provide minimal benefit to
patients.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Jonathan
Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-host-conference-call-and-webcast-on-march-10th-to-share-topline-results-from-the-phase-2a-river-trial-of-haduvio-in-patients-with-refractory-chronic-cough-302396410.html
SOURCE Trevi Therapeutics, Inc.
